PROCEPT BioRobotics Proposes Public Offering of Common Stock
PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a pioneer in surgical robotics, recently announced its intention to conduct a public offering for common stock, aiming to raise up to $175 million. In addition, a selling stockholder is set to give underwriters a 30-day option to purchase up to $26.25 million more shares. It’s important to note that the company will not benefit financially from any share sales executed by the selling stockholder. This proposed offering will depend on market conditions, and the exact details may evolve as the situation develops.
Management and Execution of the Offering
BofA Securities, Piper Sandler, and Morgan Stanley are taking the lead as joint book-running managers for this offering. Their expertise in navigating public offerings will be crucial to ensuring the success of this initiative. Since it is an underwritten offering, they will handle the sale process of the shares, creating potential benefits for investors interested in participating in this offering.
SEC Registration and Preliminary Prospectus
The shares are available under an effective shelf registration statement that PROCEPT BioRobotics filed with the U.S. Securities and Exchange Commission (SEC). This process started on August 1, 2023, indicating that the company has been preparing for this offering. Interested parties can look for a preliminary prospectus supplement concerning this offering, including all necessary details, which will be filed with the SEC.
Where to Find the Offering Details
The preliminary prospectus supplement and further details are accessible on the SEC's website. Beyond this, potential investors can also receive copies directly from BofA Securities, Piper Sandler, or Morgan Stanley once available. This connection is vital for maintaining transparency and ensuring investors have the necessary information to make informed decisions.
About the Company’s Innovations
PROCEPT BioRobotics specializes in surgical robotics dedicated to enhancing patient care through innovative solutions in urology. The company is known for its cutting-edge AQUABEAM and HYDROS Robotic Systems. Notably, the HYDROS system utilizes AI-driven technology to perform Aquablation therapy— a distinctive feature not yet found in competing products.
The Impact of Aquablation Therapy
Aquablation therapy targets men experiencing lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), a condition affecting around 40 million men in the United States. This therapy offers effective, safe, and lasting results, independent of the prostate's size or the surgeon's expertise. With over 150 peer-reviewed publications backing its efficacy, PROCEPT continues to expand its clinical portfolio, establishing itself as a leader in providing innovative urological solutions.
Understanding Business Risks
While the company shows great promise, it faces various risks as it navigates the public offering. Market dynamics, trading volatility of its common stock, and the overall business environment could influence future successes. The company’s management has acknowledged these factors and believes they’ll be critical as they push forward with their offerings and product initiatives.
Commitment to Transparency
This announcement includes forward-looking statements regarding the timing and completion of the public offering. PROCEPT BioRobotics is committed to transparently sharing any vital developments to its management and operations with stakeholders.
Contact Information for Investors
For those interested in learning more, Matt Bacso, the VP of Investor Relations and Business Operations, stands ready to address inquiries. His contact information is available, encouraging a dialogue with investors and other interested parties.
Frequently Asked Questions
What is PROCEPT BioRobotics focusing on with this offering?
They aim to raise funds for public offerings to support their innovative projects in urology.
Who are the lead managers for this stock offering?
BofA Securities, Piper Sandler, and Morgan Stanley are jointly managing the offering.
What type of technology does PROCEPT BioRobotics utilize?
They use robotic systems, including AI-driven technologies for procedures like Aquablation therapy.
What's the target demographic for their Aquablation therapy?
The therapy is designed for men suffering from lower urinary tract symptoms due to BPH.
How transparent is PROCEPT regarding their risks and potential issues?
They are committed to sharing forward-looking statements and potential risks associated with their offerings.
